Compare JOB & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOB | NXTC |
|---|---|---|
| Founded | 1893 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 24.8M |
| IPO Year | 2021 | 2019 |
| Metric | JOB | NXTC |
|---|---|---|
| Price | $0.21 | $4.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 160.5K | 75.9K |
| Earning Date | 08-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,504,000.00 | $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $1.55 |
| 52 Week High | $0.28 | $15.74 |
| Indicator | JOB | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 36.93 |
| Support Level | $0.19 | $4.20 |
| Resistance Level | $0.22 | $8.68 |
| Average True Range (ATR) | 0.01 | 0.84 |
| MACD | -0.00 | -0.11 |
| Stochastic Oscillator | 22.45 | 0.00 |
GEE Group Inc is a provider of specialized staffing solutions across the United States. The company's operating segment includes Industrial Staffing Services and Professional Staffing Services. It generates maximum revenue from the Professional Staffing Services segment. The company provides the following services, direct hire placement services, temporary professional services staffing in the fields of information technology, accounting, finance and office, engineering, and medical, and temporary light industrial staffing.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.